---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-086085"
form_type: "8-K"
ticker: "BCYC"
cik: "0001761612"
company_name: "BICYCLE THERAPEUTICS PLC"
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:21:47.022081+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bicycle Therapeutics Q2 net loss $39.8M; cash $961.4M after $555M PIPE

## Summary
- Net loss of $39.8M ($0.77 loss per share) vs $42.6M ($1.41 loss per share) in Q2 2023; R&D expense $40.1M.
- Cash and cash equivalents $961.4M as of June 30, 2024, up from $526.4M at Dec 31, 2023, after $555M PIPE financing.
- Pipeline focused on zelenectide pevedotin (BTC) and BT5528; four abstracts accepted for ESMO 2024.
- Jennifer Perry promoted to CSO & head of commercial; Nick Keen transitions to advisor; new Clinical Advisory Board formed.
- Repaid $31.9M Hercules loan in July 2024 ahead of maturity; financial runway extended into 2H 2027.

## SEC filing metadata
- accession: 0001104659-24-086085
- form_type: 8-K
- ticker: BCYC
- cik: 0001761612
- company_name: BICYCLE THERAPEUTICS PLC
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1761612/000110465924086085/0001104659-24-086085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1761612/000110465924086085/tm2420860d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-086085
- JSON: https://secwatch.observer/filing/0001104659-24-086085.json
- Plain text: https://secwatch.observer/filing/0001104659-24-086085.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.